chevron_leftBack
As of 15 June 2026, Ardelyx, Inc. has a market cap of $1.47B USD, ranking #8560 globally and #1905 in the United States.
It ranks #719 in the Healthcare sector, and #277 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$1.47BUSD
Enterprise Value
$1.45BUSD
Revenue (TTM)
$407.32MUSD
EBITDA (TTM)
-$37.92MUSD
Net Income (TTM)
-$61.6MUSD
EBITDA Margin
-9.3%
Profit Margin
-15%
Forward PE
541.0
PS Ratio
3.6
PB Ratio
8.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Michael Raab
open_in_new
Employees
489
Founded
2007
IPO
19 Jun 2014
Website
ardelyx.com
open_in_new
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.7% | -0.2% | 9.7% | -24% | 18% | 12% |
News
Loading...
ARDX Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ARDX
Ardelyx Inc
ISIN: US0396971071
Shares Out.:
Shares Outstanding:
247.029M1
Shares Float:
236.418M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
6.01 USD | |
|
41X
Ardelyx Inc
ISIN: US0396971071
|
5.06 EUR | |
|
ARDX
Ardelyx Inc
ISIN: US0396971071
|
99.00 MXN |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
52K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
37K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
24K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
18K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
10K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
8K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$320.51B
22K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
19K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$273.78B
18K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.97B
12K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
7K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
7K%
80.96B GBP
|
14.6
|
chevron_leftBack